High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma | Journal for ImmunoTherapy of Cancer

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

This article has a correction. Please see:

Correction: High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma - March 01, 2024

PDF +
Supplementary
Material

Clinical/translational cancer immunotherapy

Original research

High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma

Online download statistics by month:

Online download statistics by month: March 2024 to October 2024

	Abstract	Full	Pdf
Mar 2024	640	647	221
Apr 2024	416	419	117
May 2024	527	531	61
Jun 2024	292	296	76
Jul 2024	427	428	62
Aug 2024	230	235	54
Sep 2024	252	252	70
Oct 2024	254	254	48
Total	3038	3062	709